Aortic Valve Stenosis
Conditions
Brief summary
The aim of this collaborative analysis is to evaluate stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. In the absence of large randomized controlled trials, we will conduct a large collaborative patient-pooled meta-analysis on 30-day stroke and mortality in patients undergoing primary transfemoral TAVI with either MCV or ES valve.
Detailed description
The main aim of this patient-pooled analyses is to compare stroke rates and mortality in patients undergoing TAVI with the self-expandable MCV prosthesis compared to the balloon-expandable ES valve. However, this collaboration may also be used to compare various outcomes. Studies were included if they complied with the following requirements: original prospective studies, including patients with aortic valve stenosis treated with transfemoral TAVI of native valves and reporting of 30 day stroke outcomes according to VARC criteria or other specified corresponding criteria . Moreover, to be included studies had to report both the use of self-expandable MCV prosthesis and the balloon-expandable ES valve in more than 50 patients in each arm to ensure experience in use of the valves. Studies were excluded if they only addressed patients undergoing valve-in-valve and re-do procedures or bicuspid valves or included the same study population. Principal Investigators of these studies were approached for collaboration.
Interventions
Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
Sponsors
Study design
Eligibility
Inclusion criteria
* patients undergoing transfemoral transcatheter aortic valve procedures
Exclusion criteria
* valve-in-valve procedures, other acces routes than transfemoral
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 30 days | Death during the first month after TAVI |
| Stroke | 30 days | Stroke during the first month after TAVI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pacemaker implantation | 30 days | Pacemaker during the first month after TAVI |
| Bleeding | 30 days | Major or life-threatening bleeding during the first month after TAVI |
| New onset atrial fibrillation | 30 days | New onset atrial fibrillation during the first month after TAVI |
| Myocardial infarction | 30 days | Myocardial infarction during the first month after TAVI |
Countries
Netherlands